Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Nuvation Bio Inc. currently has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners, which means that every pending matter is being reviewed by a different individual at the USPTO. Despite this variety in examiners, the prosecution is relatively concentrated at the administrative level, as the 3 actions are located within only 2 distinct art units. PAUL V WARD is the busiest examiner for this portfolio, currently handling 1 busiest examiner pending office action.
The presence of 3 distinct examiners for 3 pending office actions means there is no examiner overlap in the current portfolio. However, the 2 distinct art units indicate that at least two examiners are operating within the same administrative group. This requires the applicant to navigate 3 different examiner styles while adhering to the technical standards of 2 distinct art units. The Biotechnology & Pharmaceuticals technology area provides the overarching context for all 3 pending office actions. Practitioners should note that the busiest examiner, PAUL V WARD, only handles 1 busiest examiner pending office action, matching the workload of the other examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WARD, PAUL V | 1 | 83.2% | -12.2% |
| RAHMANI, NILOOFAR | 1 | 77.6% | -2.9% |
| GONZALEZ, LUISALBERTO | 1 | 59.7% | +46.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18866777 | METHOD FOR PRODUCING 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | WARD, PAUL V | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18575414 | CRYSTALLINE FORMS OF 3-{4-[(2R)-2-AMINOPROPOXY]PHENYL}-N-[(1R)- 1-(3-FLUOROPHENYL) ETHYL]IMIDAZO[1,2-B]PYRIDAZIN-6-AMINE AND SALTS THEREOF | GONZALEZ, LUISALBERTO | 13d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18575414 | CRYSTALLINE FORMS OF 3-{4-[(2R)-2-AMINOPROPOXY]PHENYL}-N-[(1R)- 1-(3-FLUOROPHENYL) ETHYL]IMIDAZO[1,2-B]PYRIDAZIN-6-AMINE AND SALTS THEREOF | GONZALEZ, LUISALBERTO | 13d |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18866777 | METHOD FOR PRODUCING 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | WARD, PAUL V | 1622 | §103 | Non-Final OA | — | Pending | Nov 18, 2024 |
| 18915226 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | RAHMANI, NILOOFAR | — | §112Other | Non-Final OA | — | Pending | Oct 14, 2024 |
| 18575414 | CRYSTALLINE FORMS OF 3-{4-[(2R)-2-AMINOPROPOXY]PHENYL}-N-[(1R)- 1-(3-FLUOROPHENYL) ETHYL]IMIDAZO[1,2-B]PYRIDAZIN-6-AMINE AND SALTS THEREOF | GONZALEZ, LUISALBERTO | 1624 | §102§112 | Final Rejection | 13d | Pending | Dec 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNuvation Bio Inc. has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Paul V Ward has the most, with 1 of Nuvation Bio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
